Julie Faltum

Julie Faltum is a Senior Advisor and a distinguished biopharmaceutical executive with over 20 years of experience delivering transformational value to the healthcare ecosystem. Her career, spanning major markets in the U.S. and Europe, includes executive leadership roles at industry giants such as Novo Nordisk, Lundbeck, Sanofi, and Mallinckrodt, as well as strategic management consulting for high-growth biotechs.

A specialist in asset management and commercial development, Julie spent a decade at the Vice President level, leading programs across hemostasis, metabolism, and rare diseases. During her tenure at Novo Nordisk, she was instrumental in the global development of rFVIIa (NovoSeven), co-leading Phase 3 trauma and Phase 2 cardiac surgery programs while orchestrating engagement with global scientific thought leaders.

Known for her commercial acumen, Julie has led three successful global product launches, including the blockbuster GLP-1 Victoza for Type 2 Diabetes. Based in the U.S., she now counsels European ventures on technology transfer and venture building. Julie holds a MSc in International Business from Copenhagen Business School and a postgraduate degree in Pharmaceutical Medicine from the University of Basel.